Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 + abiraterone + prednisone vs placebo + abiraterone + prednisone in chemotherapy-naive bone-predominant metastatic castration-resistant prostate cancer
jRCT2080223263Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Radium-223 + abiraterone + prednisone/prednisolone with Placebo + abiraterone + prednisone/prednisolone (2 arms). Primary endpoint: Time to skeletal-related events (SSE) or death. Started Jul 2016; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080223263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223263.